Organisation paid for research Program year 2024 Source: CMS Open Payments

Synergy Group US LLC

Neither a doctor nor a teaching hospital

Research payments

$1,527,224

215 payments

Through program year 2024, Synergy Group US LLC is reported as receiving $1,527,224 in research payments, across 215 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$2,950	1
2023	Research	$234,430	24
2022	Research	$484,363	61
2021	Research	$582,706	69
2020	Research	$222,775	60

Breakdown

Who paid Research payments · program years 2020–2024

GlaxoSmithKline, LLC. $1,400,787 177 payments
Supernus Pharmaceuticals, Inc. $66,071 14 payments
Allergan Inc. $14,073 10 payments
Eli Lilly and Company $12,850 2 payments
Lexicon Pharmaceuticals, Inc. $11,858 1 payment
Bausch Health US, LLC $11,365 2 payments
Vifor (International) Ltd. $7,270 8 payments
Amgen Inc. $2,950 1 payment

Studies the money was for Research payments · program years 2020–2024

A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO $1,400,787 177 payments
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) $61,198 11 payments
A Randomized, Controlled Pragmatic Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $12,850 2 payments
Efc-14875 $11,858 1 payment
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) $11,365 2 payments
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) $9,559 8 payments
Diamond Pat-Cr-302 $7,270 8 payments
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) $4,514 2 payments
Assessment of Efficacy and Safety of Spn-810 for the Treatment of Impulsive Aggression (Ia) in Adolescent Subjects With Attention Deficit/Hyperactivity Disorder (Adhd) in Conjunction With Standard Adhd Treatment $3,598 2 payments
Cognitive Interviews for UC-PRO Phase 2 anchors $2,950 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.